Delving into the Latest Updates on Rimexolone with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Rimexel, Rimexolon, Rimexolone (USP/INN)

+ [8]

Target

GR

Mechanism

GR agonists(Glucocorticoid receptor agonists)

Therapeutic Areas

Eye Diseases

Active Indication

Uveitis

Inactive Indication

Dry Eye SyndromesPost procedural inflammationUveitis, Anterior

Originator Organization

Alcon AG

Active Organization-

Inactive Organization

Harrow, Inc.Alcon Research Ltd.

Drug Highest PhaseApproved

First Approval Date

US (30 Dec 1994),

Post procedural inflammationUveitis, Anterior

Regulation-

Login to view timeline

Structure

Molecular FormulaC24H34O3

InChIKeyQTTRZHGPGKRAFB-OOKHYKNYSA-N

CAS Registry49697-38-3

This study aims to compare the effects of topical (Rimexolone versus Dexamethasone) on the IOP in children under 13 years of age who underwent bilateral strabismus surgery, and to compare the effects of topical (Rimexolone versus Fluorometholone) on the IOP in the children under 13 years of age who underwent bilateral strabismus surgery.

Start Date01 Oct 2015

Sponsor / Collaborator

Cairo University

NCT00471419 / CompletedPhase 3

Phase II Study of AL-2178 (FID 109980) in the Treatment of Dry Eye

The purpose of this study is to see if Rimexolone (FID 109980) is a safe and effective treatment of dry eye.

Start Date01 Jul 2006

Sponsor / Collaborator

Alcon Research Ltd.

100 Clinical Results associated with Rimexolone

Login to view more data

100 Translational Medicine associated with Rimexolone

Login to view more data

100 Patents (Medical) associated with Rimexolone

Login to view more data

45

Literatures (Medical) associated with Rimexolone

01 Jan 2021·BioengineeredQ4 · BIOLOGY

Comprehensive analysis of lncRNA-miRNA-mRNA regulatory networks for microbiota-mediated colorectal cancer associated with immune cell infiltration

Q4 · BIOLOGY

ArticleOA

Author: Yang, Weimin ; Chen, Zhikang ; Mao, Linfeng ; Chen, Zihua ; Tan, Xiangzhou ; Huang, Changhao ; Guo, Jianping

Recent findings have identified microbiota as crucial participants in many disease conditions, including cancers. Competing endogenous RNA (ceRNA) is regarded as a candidate mechanism involving relevant biological processes. We therefore constructed a ceRNA network using the TCGA and GEO database, to determine the potential mechanisms of microbiota-mediated colorectal carcinogenesis and progression. We found a total of 75 lncRNAs, 8 miRNAs, and 9 mRNAs in the probiotics-mediated ceRNA network and a total of 49 lncRNAs, 4 miRNAs, and 3 mRNA in the pathobiont-mediated ceRNA network, which could induce the microbiota-mediated carcinogenesis and progression. The GO and KEGG analysis indicated that the ceRNA network is mainly enriched in the metabolic process, and two unique pathways (the p53 signaling pathway and microRNA in cancer), respectively. A four-gene signature (FRMD6-AS2, DIRC3, LIFR-AS1, and MRPL23-AS1) was suggested as an independent prognostic factor. Four lncRNAs (LINC00355, KCNQ1OT1, LINC00491, and HOTAIR) were associated with poor survival. Three small molecule candidate anticancer drugs (Pentoxyverine, Rimexolone, and Doxylamine) were identified. A four-gene signature (FAM129A, BCL2, PMAIP1, and RPS6) is significantly correlated with immune infiltration level. This study provides a promising biomarker reservoir to explore the mechanism by which microbiota regulate the ceRNA network involving the immune response, and further participate in colorectal carcinogenesis and progression.

01 May 2020·International ophthalmologyQ4 · MEDICINE

Outcome and risk of ocular complications of managing children with chronic anterior uveitis with topical rimexolone 1%

Q4 · MEDICINE

Article

Author: Zhang, Xiaozhe ; Gepstein, Raz ; Sharief, Lazha ; Wei, Ruoxin ; Tomkins-Netzer, Oren ; Lightman, Sue ; Chen, Yi-Hsing ; Tseng, Hsiao-Jung

PURPOSE:

To investigate the efficacy and safety of 1% rimexolone ophthalmic suspension in children with chronic anterior uveitis under real-life conditions in a tertiary center.

METHODS:

This is a retrospective longitudinal study. Medical records were analyzed at baseline, 1, 3, 6 and 12 months before and after switching to rimexolone for best-corrected visual acuity (BCVA), oral steroid use, number of flares, IOP and anti-glaucoma management.

RESULTS:

Twenty-four patients (41 eyes) diagnosed with either anterior uveitis (n = 25, 60.0%) or panuveitis (n = 16, 40%) were enrolled. The mean age was 10.5 years (4-16 years). The number of patients requiring oral prednisolone reduced from 8 patients (32.0%) at baseline to 3 patients (20.0%) at 12 months (P < 0.001). Following baseline, the median number of uveitis flares reduced from 2.0 (inter-quartile range (IQR) 1.0-2.75) to 1.0 (IQR 0.0-1.0) compared to the 12 months before baseline (P < 0.001). The mean IOP reduced from baseline (22.0 ± 7.3 mmHg) to 1 month (18.8 ± 8.7 mmHg, P = 0.01) and remained stable up to 12 months (15.9 ± 5.0 mmHg, P < 0.001). Average BCVA, dose of oral prednisolone and anti-glaucoma treatments did not change compared to the baseline. The development for IOP ≥ 30 mmHg was associated with a known corticosteroid response [odds ratio (OR) 6.8, P = 0.003] and a dose > 7.5 mg/day oral prednisolone (OR 4.4, P = 0.033).

CONCLUSIONS:

Rimexolone 1% ophthalmic suspension is an effective and safe topical steroid for pediatric anterior uveitis.

01 Jan 2020·CorneaQ3 · MEDICINE

Long-term Outcomes on de novo Ocular Hypertensive Response to Topical Corticosteroids After Corneal Transplantation

Q3 · MEDICINE

Article

Author: Salvador-Culla, Borja ; Figueiredo, Francisco Carlos ; Raj, Akash ; Anwar, Hamed ; Sykakis, Evripidis ; Figueiredo, María Socorro

Purpose::

To determine incidence, demographics, management, and outcomes of topical steroid-induced ocular hypertension after penetrating keratoplasty (PKP) and to establish effects on intraocular pressure (IOP) and graft rejection when alternate corticosteroids are used.

Methods::

A single-center, retrospective review of 568 consecutive PKPs performed between 1997 and 2010 was conducted. Data were collected on demographics, best-corrected visual acuity, surgical indications, lens status, IOP, postoperative management, and incidence of rejection.

Results::

Eighty eyes (14.1%) of 74 patients were included. The most common indication was keratoconus (28.8%). Twenty-seven eyes (33.8%) were phakic, 46 (57.4%) had a posterior chamber intraocular lens, and 7 (8.8%) had an anterior chamber intraocular lens. Mean postoperative IOP increase was only significant in the anterior chamber intraocular lens group (18.7 mm Hg, SD 10.4; P = 0.02). The average time for developing hypertension was 9.8 months (SD 14.8) postoperatively, with an average IOP increase of 13.3 mm Hg (SD 5.9). Prednisolone acetate 1% was switched to rimexolone 1% in 64 eyes (80%) and to fluorometholone 0.1% in 16 eyes (20%), which alone achieved IOP normalization in 26 eyes (32.5%) (P < 0.01). Fifty-four eyes (67.5%) required additional antiglaucoma medication. An average IOP reduction of 12.3 mm Hg (SD 6.9) was achieved at an average of 2.3 months (SD 5.2) after the switch. Seventeen eyes (21%) developed glaucoma and 13 eyes (16.3%) developed graft rejection after switching formulations, with no statistically significant differences between rimexolone and fluorometholone (P > 0.05).

Conclusions::

The use of alternate topical corticosteroids may be considered in cases of steroid-induced ocular hypertension after PKP because they offer good antiinflammatory prophylaxis with reduced hypertensive response.

100 Deals associated with Rimexolone

Login to view more data